**Core Concept**
The treatment of malignant melanoma involves immunotherapy, which aims to stimulate the body's immune response to recognize and destroy cancer cells. In this context, immunostimulants are substances that enhance the immune system's ability to fight cancer.

**Why the Correct Answer is Right**
Aldesleukin, also known as interleukin-2 (IL-2), is a recombinant DNA-derived interleukin that stimulates the proliferation of T cells and natural killer cells, which play a crucial role in the immune response against cancer cells. By enhancing T cell activity, aldesleukin helps to boost the immune system's ability to recognize and target malignant melanoma cells. This mechanism is particularly effective in treating metastatic melanoma, where the immune system's ability to recognize and destroy cancer cells is often impaired.

**Why Each Wrong Option is Incorrect**
**Option A:** Levamisole is an immunomodulatory agent that has been used to enhance the immune response in various conditions, including cancer. However, it is not a specific immunostimulant used for the treatment of malignant melanoma.

**Option B:** BCG (Bacillus Calmette-Guérin) is a live, attenuated vaccine used primarily for the prevention of tuberculosis. While BCG has been used as an immunostimulant in some cancer treatments, it is not specifically used for the treatment of malignant melanoma.

**Option D:** Methotrexate is a chemotherapeutic agent that is used to treat various types of cancer, including leukemia and lymphoma. However, it is not an immunostimulant and does not work by enhancing the immune response.

**Clinical Pearl / High-Yield Fact**
Aldesleukin (IL-2) is a high-risk medication that requires careful monitoring due to the risk of severe side effects, including capillary leak syndrome, which can lead to hypotension, respiratory distress, and even death.

**✓ Correct Answer: C. Aldesleukin**